Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma
A phase 2 trial of ONC206 in pheochromocytoma and paraganglioma, run by Jazz Pharmaceuticals, now recruiting.
Overview
Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma is a phase 2 interventional study registered as NCT07282587 by Jazz Pharmaceuticals, with 90 participants planned, started 2026-01-02 and due to reach its primary completion in 2028-12-15. Interventions recorded: ONC206, ONC206: Dose 1 and ONC206: Dose 2.
Setting
A Phase 2 Study of ONC206 in Advanced Pheochromocytoma and Paraganglioma
Phase
Phase 2
Sponsor
Jazz Pharmaceuticals
Registry
Enrolled
90